Related Experiment Videos
A high frequency of N-RAS oncogene mutations in multiple myeloma
Abstract:
Mutation of the RAS oncogene was studied in ten patients with multiple myeloma, and the DNA from nude mouse tumors formed by cells obtained from tumorigenecity assays (in vivo selection assays) in these patients was analyzed by PCR and oligonucleotide hybridization. Mutations of the N-RAS oncogene were identified in two of three patients investigated by in vivo selection assay and in five of ten patients investigated by PCR analysis of DNA from myeloma cells. In the two former patients, mutation of the N-RAS oncogene was observed at the 61st codon. Of the five N-RAS mutant-positive patients investigated by the PCR analysis, one had a mutation at codon 12, two had mutations at codon 13, and two had mutations at codon 61. None of the patients had mutations of the K-RAS oncogene. These results suggest that the frequency of RAS gene mutation in multiple myeloma is higher than in other lymphoid malignancies such as acute lymphocytic leukemia, chronic lymphocytic leukemia, and malignant lymphoma. As the mutation was observed only at the N-RAS oncogene level, it is speculated that N-RAS oncogene activation might play an important role in the progression of multiple myeloma.
Insights
RAS oncogene mutations, particularly in the N-RAS gene, are more frequent in multiple myeloma than other lymphoid cancers. N-RAS activation may drive multiple myeloma progression.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Multiple myeloma is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
- RAS oncogenes are frequently mutated in various human cancers, but their role in multiple myeloma is less understood.
Purpose of the Study:
- To investigate the frequency and types of RAS oncogene mutations in patients with multiple myeloma.
- To compare RAS mutation frequency in multiple myeloma with other lymphoid malignancies.
Main Methods:
- DNA analysis using Polymerase Chain Reaction (PCR) and oligonucleotide hybridization.
- In vivo selection assays using nude mouse tumors derived from patient myeloma cells.
Main Results:
- N-RAS oncogene mutations were detected in 5 out of 10 multiple myeloma patients via PCR.
- Mutations were identified at codons 12, 13, and 61 of the N-RAS gene.
- No mutations were found in the K-RAS oncogene; N-RAS mutations were more frequent than in other lymphoid cancers.
Conclusions:
- RAS gene mutations, specifically N-RAS, occur more frequently in multiple myeloma than previously reported for other lymphoid malignancies.
- N-RAS oncogene activation is implicated as a potential driver in the progression of multiple myeloma.